The use of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients

B. Savoldo; H. E. Heslop; C. M. Rooney

doi:10.3109/10428190009113376

The use of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients

B. Savoldo, H. E. Heslop, C. M. Rooney

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Epstein-Barr Virus Lymphoproliferative Diseases (EBV-LPD) can affect patients receiving allogeneic hemopoietic stem cell or solid organ transplant. They are caused by impairment of EBV specific CD8+ cytotoxic T-lymphocyte (CTL) response due to the immunosuppression that follows these procedures. Despite different therapies LPD can still have a rapid and lethal course. A promising solution is the application of adoptive immunotherapy approaches such as ex vivo generated EBV-specific CTLs for prevention and therapy. Their infusion has been demonstrated to be safe and effective in allogeneic hemopoietic stem cell transplant recipients and their use after allogeneic solid organ transplant is also under evaluation.

Original language	English (US)
Pages (from-to)	455-464
Number of pages	10
Journal	Leukemia and Lymphoma
Volume	39
Issue number	5-6
DOIs	https://doi.org/10.3109/10428190009113376
State	Published - 2000

Keywords

Cytotoxic Tcells
EBV-induced lymphoma
Prevention
Transplantation
Treatment

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428190009113376

Cite this

@article{4f0c79201bae4c7784294b24c3c17df5,

title = "The use of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients",

abstract = "Epstein-Barr Virus Lymphoproliferative Diseases (EBV-LPD) can affect patients receiving allogeneic hemopoietic stem cell or solid organ transplant. They are caused by impairment of EBV specific CD8+ cytotoxic T-lymphocyte (CTL) response due to the immunosuppression that follows these procedures. Despite different therapies LPD can still have a rapid and lethal course. A promising solution is the application of adoptive immunotherapy approaches such as ex vivo generated EBV-specific CTLs for prevention and therapy. Their infusion has been demonstrated to be safe and effective in allogeneic hemopoietic stem cell transplant recipients and their use after allogeneic solid organ transplant is also under evaluation.",

keywords = "Cytotoxic Tcells, EBV-induced lymphoma, Prevention, Transplantation, Treatment",

author = "B. Savoldo and Heslop, {H. E.} and Rooney, {C. M.}",

note = "Funding Information: This work was supported by NIH grants CA 61384, CA 74126 and the General Clinical Research Center at Baylor College of Medicine.",

year = "2000",

doi = "10.3109/10428190009113376",

language = "English (US)",

volume = "39",

pages = "455--464",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "5-6",

}

TY - JOUR

T1 - The use of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients

AU - Savoldo, B.

AU - Heslop, H. E.

AU - Rooney, C. M.

N1 - Funding Information: This work was supported by NIH grants CA 61384, CA 74126 and the General Clinical Research Center at Baylor College of Medicine.

PY - 2000

Y1 - 2000

N2 - Epstein-Barr Virus Lymphoproliferative Diseases (EBV-LPD) can affect patients receiving allogeneic hemopoietic stem cell or solid organ transplant. They are caused by impairment of EBV specific CD8+ cytotoxic T-lymphocyte (CTL) response due to the immunosuppression that follows these procedures. Despite different therapies LPD can still have a rapid and lethal course. A promising solution is the application of adoptive immunotherapy approaches such as ex vivo generated EBV-specific CTLs for prevention and therapy. Their infusion has been demonstrated to be safe and effective in allogeneic hemopoietic stem cell transplant recipients and their use after allogeneic solid organ transplant is also under evaluation.

AB - Epstein-Barr Virus Lymphoproliferative Diseases (EBV-LPD) can affect patients receiving allogeneic hemopoietic stem cell or solid organ transplant. They are caused by impairment of EBV specific CD8+ cytotoxic T-lymphocyte (CTL) response due to the immunosuppression that follows these procedures. Despite different therapies LPD can still have a rapid and lethal course. A promising solution is the application of adoptive immunotherapy approaches such as ex vivo generated EBV-specific CTLs for prevention and therapy. Their infusion has been demonstrated to be safe and effective in allogeneic hemopoietic stem cell transplant recipients and their use after allogeneic solid organ transplant is also under evaluation.

KW - Cytotoxic Tcells

KW - EBV-induced lymphoma

KW - Prevention

KW - Transplantation

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0034486995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034486995&partnerID=8YFLogxK

U2 - 10.3109/10428190009113376

DO - 10.3109/10428190009113376

M3 - Article

C2 - 11342329

AN - SCOPUS:0034486995

SN - 1042-8194

VL - 39

SP - 455

EP - 464

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 5-6

ER -

The use of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this